A New Year Filled With Debate Over Drug Pricing, PwC Predicts
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug pricing and M&A top PwC’s Health Research Institute annual report highlighting the top issues impacting the health care sector in the year ahead.
You may also be interested in...
No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017
Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters anticipated to enter the market next year.
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza
Tools that provide transparent, comparative information about the efficacy, drawbacks and costs of a range of treatment options are helping patients, clinicians and payers choose drugs wisely. They're also forcing pharma to link price more explicitly to value.
FDA Biosimilar Education Campaign Will Need To Be Targeted
Sen. Cassidy does not think additional appropriations are needed for a massive provider and patient education on biosimilars.